Significance:
Given that (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) the life-long painful injection/drug treatment required to treat DM; and (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult β-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural product-based drug.
This study suggests an MiRNA-based Regenerative therapy for DM. MiRNA-200a-3p, by decreasing the expression of its target gene, it may: (1) increase the expression of modulator of lipid homeostasis liver X receptor (LXR)-α; (2) decrease plasma levels of triglyceride and cholesterol; (3) protect against diet-induced weight-gain; and (4) increase insulin-secreting cell mass and function. Thereby, it may increase insulin sensitivity and leanness. Thus, pharmacological formulations encompassing “MiRNA-200a-3p or its activators” can be used to treat metabolic disorders.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, Molecular therapy for Metabolic disorders: MiRNA-200a-3p increases (LXR)-α expression, decreases triglyceride and cholesterol levels, increases insulin sensitivity and promotes leanness via down regulation of its target genes, 15/October/2016, 6.50 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org or http://newbioideas.com
Courtesy: When you cite drop us a line at info@genomediscovery.org
Amount: $150
Undisclosed information: How MiRNA-200a-3p increases (LXR)-α expression and promotes insulin-sensitivity
Results guaranteed if not refunded
# Research cooperation